Senseonics Holdings, Inc.

Senseonics is a medical technology company that develops and commercializes implantable continuous glucose monitoring (CGM) systems under the Eversense brand, including Eversense E3 and Eversense 365. The company's systems measure interstitial glucose levels via an under-the-skin sensor, paired with a removable and rechargeable smart transmitter and a mobile application for real-time monitoring and vibratory alerts. Its products serve individuals managing diabetes, as well as the healthcare professionals and proceduralists who prescribe and insert the devices.

The company is headquartered in Germantown, Maryland. Its commercial and distribution footprint spans the United States and select European countries, including Italy, Germany, Spain, and Sweden, alongside other European Economic Area markets. In the United States, Senseonics supports patient access through its dedicated sales organization, fulfillment partners, and an inserter network operating across approximately 30 states. Manufacturing operations are outsourced to contract facilities located in North America and Europe.

Summary of the business section of Senseonics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 130 full-time employees, of whom over half hold Ph.D., M.D., master’s degree, or other post graduate degrees, and all of whom are in the United States.”